Mergers & Acquisitions ·
Bio-Techne Corporation reported fourth quarter fiscal 2026 results ending June 30, 2026
TECHBIO-TECHNE Corp
Bio-Techne Corporation reported fourth quarter fiscal 2026 results ending June 30, 2026. Net sales increased 1% to $321.2 million, with organic revenue up 3%. GAAP diluted EPS rose to $0.35 from a loss of $(0.11) in the prior year period, while adjusted diluted EPS was $0.52. Full-year net sales remained flat at $1.2 billion, and full-year GAAP diluted EPS increased to $1.16 from $0.46. The company reiterated its agreement to be acquired by Merck KGaA for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. Bio-Techne also announced a quarterly cash dividend of $0.08 per share, payable September 4, 2026, to shareholders of record on August 24, 2026. The company operates in the life sciences industry, providing reagents, analytical instruments, and precision diagnostics.